NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
ImmuneSensor Therapeutics Inc.
TransThera Sciences (Nanjing), Inc.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Abramson Cancer Center at Penn Medicine